Corporate Update: ResMed Inc. Expands U.S. Distribution Infrastructure

ResMed Inc., a leading provider of connected medical devices for sleep and respiratory care, announced the planned construction of a new distribution centre in Greenwood, Indiana. Operations at the site are slated to commence in 2027, with the primary objective of enhancing the company’s domestic distribution capacity and reinforcing supply‑chain resilience across North America.

Strategic Rationale

The decision aligns with ResMed’s broader strategic imperative to strengthen its presence in the United States, a market that accounts for a substantial proportion of the company’s revenue. By increasing logistical flexibility and shortening transit times to regional hubs, ResMed aims to:

  1. Reduce lead times for critical therapeutic devices, including continuous positive airway pressure (CPAP) units and ventilatory support systems.
  2. Mitigate supply‑chain disruptions that have historically impacted the respiratory therapy sector, particularly during periods of heightened demand (e.g., the COVID‑19 pandemic).
  3. Support scalability for emerging product lines, such as high‑definition CPAP technology and integrated patient‑monitoring platforms.

Operational and Safety Considerations

The Greenwood facility will be designed to meet stringent industry standards for the storage and handling of medical devices. Key safety and compliance measures include:

  • Temperature‑controlled storage to preserve device integrity, particularly for components susceptible to degradation under extreme conditions.
  • Automated inventory management systems leveraging real‑time data analytics to minimize stockouts and excess inventory, thereby reducing the risk of device obsolescence.
  • Redundant power and backup systems to ensure uninterrupted operation, a critical requirement for time‑sensitive medical equipment.

Regulatory oversight will be maintained in accordance with the U.S. Food and Drug Administration (FDA) and the International Organization for Standardization (ISO) 13485:2016 quality management standard for medical device manufacturing and distribution. The facility will undergo periodic audits to verify compliance with these frameworks.

Efficacy Outcomes and Patient Impact

ResMed’s portfolio of respiratory devices has demonstrated robust efficacy in improving sleep quality and reducing apnea‑hypopnea index (AHI) scores. A 2025 meta‑analysis encompassing 12 randomized controlled trials (RCTs) reported a mean reduction in AHI of 14.6 events per hour (95% CI: 12.4–16.8) for CPAP therapy compared with sham controls. The new distribution centre is expected to:

  • Accelerate device availability at regional medical centers, potentially shortening the interval between diagnosis and therapy initiation.
  • Enable rapid deployment of firmware updates and patient‑specific calibration data, enhancing overall treatment effectiveness.
  • Facilitate access to emerging modalities such as adaptive servo‑ventilation (ASV) and bilevel positive airway pressure (BiPAP), which require precise titration and monitoring.

By improving distribution efficiency, ResMed anticipates a measurable impact on adherence rates, which are directly correlated with therapeutic efficacy.

Regulatory Pathways and Market Expansion

The introduction of the Greenwood distribution hub coincides with ResMed’s ongoing regulatory submissions for several next‑generation devices:

  • Next‑generation CPAP devices equipped with adaptive flow control and AI‑driven leak compensation, currently under 510(k) clearance with the FDA.
  • Integrated patient‑monitoring platforms that comply with the FDA’s Digital Health Software Precertification Program, facilitating expedited market entry.

The enhanced domestic logistics network will support these regulatory milestones by ensuring timely delivery of devices to trial sites and post‑market surveillance points. Furthermore, the facility’s proximity to major distribution corridors—intersecting interstates I‑65 and I‑74—will streamline cross‑border shipments to Canada and Mexico, expanding ResMed’s footprint within the North American Free Trade Agreement (NAFTA) zone.

Practical Implications for Healthcare Systems

Healthcare providers can anticipate several operational benefits:

  • Reduced inventory holding costs due to improved forecast accuracy and just‑in‑time delivery schedules.
  • Lowered device downtime, translating into better patient throughput and resource allocation in sleep laboratories.
  • Enhanced data synchronization between devices and electronic health records (EHRs), supporting evidence‑based treatment adjustments.

In turn, payers and insurers may observe cost savings associated with optimized device utilization and decreased need for costly emergency interventions stemming from device failure or suboptimal therapy.

Conclusion

ResMed Inc.’s planned distribution centre in Greenwood, Indiana, represents a strategic investment in supply‑chain robustness and patient‑centric delivery. By aligning logistical upgrades with rigorous safety standards and regulatory compliance, the company positions itself to sustain high‑quality respiratory care across North America while supporting the evolving needs of clinicians and patients alike.